Skip to Content

Alseres Pharmaceuticals Inc - Stock Quote ALSE

Rating as of

Morningstar's Alseres Pharmaceuticals Inc Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics - ALSE

Alseres Pharmaceuticals Inc's Company Profile

Business Description

Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company’s lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.

Contact
275 Grove Street, Suite 2-400
Auburndale, MA, 02466
T +1 508 497-2360
Industry Biotechnology
Most Recent Earnings Jun 30, 2014
Fiscal Year End Dec 31, 2014
Stock Type Distressed
Employees 3